New Weight-Loss drug AZD6234 passes early safety test in 104 volunteers
NCT ID NCT06132841
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 25 times
Summary
This early-stage study tested a new drug called AZD6234 in 104 healthy adults with overweight or obesity. The main goal was to check if repeated doses are safe and tolerable compared to a placebo. Researchers also measured how the drug moves through the body. This is a first step to see if AZD6234 could help manage weight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Glendale, California, 91206, United States
-
Research Site
Brooklyn, Maryland, 21225, United States
-
Research Site
Osaka, 532-0003, Japan
Conditions
Explore the condition pages connected to this study.